VISCHER advises Relief Therapeutics regarding all legal aspects of this transaction.
RELIEF THERAPEUTICS Holding AG, a biopharmaceutical company with its lead compound RLF-100TM (aviptadil) in advanced clinical development to treat COVID-19-induced lung injury, and APR Applied Pharma Research S.A. (APR), a privately held Swiss pharmaceutical company with over 25 years’ experience in identifying, developing and commercializing known molecules engineered with drug delivery systems in niche and rare diseases on a global basis, announced that the companies have signed a binding term sheet for Relief to acquire all outstanding shares of APR. According to the Term Sheet, the APR shareholders will receive from Relief at the closing of a signed transaction, CHF 22m in cash, plus additional cash relating to APR’s working capital position at time of close, and CHF 50m payable in Relief common registered shares. The APR shareholders are also eligible to receive additional contingent payments in the form of a combination of cash and Relief common registered shares upon achievement of pre-agreed contingent milestones.
The VISCHER team led by partner Dr. Robert Bernet (Picture – Corporate/M&A) comprises Dr. Peter Kühn (Counsel, Corporate/M&A), Christian Schneiter (Associate, Corporate/M&A), Florian Kambor and Lukas Wendt (Junior Associates, Corporate/M&A) and Gian Geel (Associate, Employment).
Law Firms: VISCHER AG;
Clients: Relief Therapeutics;